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interventional and 24-week observational study. Treatment costs were derived 
from drug retail prices in Chinese market. Diabetes management and 
complication costs were obtained from Chinese published data. Projections were 
made from a societal perspective for 30 years, with costs and life years 
discounted at 3% annually. One-way sensitivity analysis was performed. 
RESULTS: Switching to IAsp from HI was projected to increase life expectancy by 
0.48 year (14.11 vs. 13.63) and QALY by 0.96 QALY per patient (9.83 vs. 8.87), due 
to reduced incidences of diabetes-related complications. IAsp was associated 
with reduced total direct medical costs by CNY (Chinese Yuan) 108,464 (204,853 
vs. 313,317), due to reduced complication costs by CNY 129,778 (107,084 vs. 
236,862) and increased treatment and management costs of CNY (Chinese Yuan) 
20,128 (57,391 vs. 37,263) and 1,186 (40,378 vs. 39,192) respectively. Sensitivity 
analyses demonstrated robustness of the results. CONCLUSIONS: Switching to 
IAsp from HI for Chinese patients with T2DM on a basal-bolus regimen was not 
only associated with improvements in life expectancy and QALYs, but also 
significant reduction in total direct medical costs. Switching to IAsp from HI on a 
basal-bolus regimen is a cost-saving treatment strategy for T2DM patients in a 
Chinese setting.  
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OBJECTIVES: The Cardiff Type-2 Diabetes Model is a fixed time increment 
stochastic simulation model written in Microsoft Excel and C++; initially 
developed in 2003, it has been used to support a number of cost-effectiveness 
and public health policy decisions. The model is fundamentally built around the 
risk equations reported from the United Kingdom Prospective Diabetes Study 
(UKPDS) and concerns persist regarding the validity of these equations in 
contemporary populations. Therefore, the objective of this study was to validate 
the model’s output to recently published outcomes trials to establish if the 
UKPDS equations remain credible. METHODS: Simulated cohorts reflecting the 
baseline characteristics associated with key outcomes studies (ASPEN, 
ADVANCE, ACCORD, VADT, ADDITION, ASCOT, CARDS and long term follow-up 
of UKPDS) were generated and treatment effects applied to reflect intensive 
versus conventional arms. Predicted and observed events, over a time horizon 
consistent with each trial, were compared and goodness of fit determined, using 
the coefficient of determination (R2). RESULTS: Across all validation studies 
predicted versus observed events resulted in an R2 statistic of 0.90. This result 
was obtained when including data from UKPDS, for which the model gave an 
exceptionally fit (R2 = 0.95) When excluding UKPDS the overall R2 = 0.7. Despite 
the less accurate fit, there was a consistent trend demonstrated from the model 
although a noteworthy lack of fit was observed for the ACCORD blood pressure 
trial (non-fatal myocardial infarctions [MI]) and ACCORD glucose lowering trial 
(non- fatal MI and congestive heart failure) in which the predicted events rates 
by the model were substantially lower than reported in the trials. Similarly, for 
the ADVANCE trial, non-fatal strokes were significantly under-predicted by the 
model. CONCLUSIONS: This study suggests the UKPDS risk equations within 
type-2 diabetes models remain credible for supporting contemporary technology 
assessment and health policy decisions.  
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OBJECTIVES: Long-acting insulin analogues are currently not reimbursed  
in diabetes type-2 in Poland. The population who could benefit most from its 
reimbursement are patients whose glycaemic control cannot be maintained 
using protamine Hagedorn insulin (NPH). The aim of the analysis was to assess 
cost-effectiveness of insulin glargine (IGlar) as compared to NPH in treatment  
of such subpopulation. METHODS: Cost-utility analysis in lifetime horizon was 
conducted using widely validated CORE Diabetes Model. This is a commonly 
used Markov model which simulates the progression of physiological parameters 
and incidence of diabetes-related complications over time. The analysis  
was based on systematic literature review of clinical trials. Due to lack of data 
from RCTs for the subpopulation defined as lack of NPH efficacy, the data source 
were non-randomized clinical trials. These are so far the best available evidence. 
Based on the identified studies two comparisons were made: IGlar versus NPH, 
both in combination with oral antidiabetic drugs (OAD) or with OAD / bolus 
insulin. The following efficacy parameters were taken into account: change  
in HbA1c, BMI, hypoglycemia rate. Costs were estimated from public payer’s 
(National Health Fund, NHF), and NHF+patients’ perspective. Costs, quality-
adjusted life years (QALYs) and incremental cost-utility ratios (ICURs)  
were estimated as a result of modeling. Annual discount rates of 5% and 3.5% 
were applied on costs and health effects, respectively. The acceptability 
threshold was set at 25,800 EUR/QALY. RESULTS: The difference in QALY was 
0.792 for IGlar+OAD vs NPH+OAD and 0.695 for IGlar+OAD/bolus versus 
NPH+OAD/bolus. From NHF+patients’ perspective the difference in costs was 
1592 EUR and 1355 EUR, respectively. ICURs were 2010 EUR and 1950 EUR, 
respectively. Results from NHF perspective were similar – ICURs did not exceed 
2000 EUR. CONCLUSIONS: In Polish setting insulin glargine is highly cost-
effective in patients in whom NPH insulin does not provide adequate glycaemic 
control.  
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OBJECTIVES: Type-2 diabetes mellitus (T2DM) is a complex chronic disease; 
consequently, T2DM cost-effectiveness models are invariably complex. Despite 
efforts to validate these models and promote transparency it is often unclear to 
decision makers how these models map input settings to output results and 
which factors are most influential. Therefore, the objective of this study was to 
assess the relative impact of three key components of diabetes therapy on cost-
effectiveness: changes in HbA1c, hypoglycemia and body mass index (BMI). 
METHODS: This study utilized the IMS CORE diabetes model (CDM) to model four 
profiles associated with managing type 2 diabetes; Treatment 1: -0.5% HbA1c; 
Treatment 2: -0.5% HbA1c and BMI -1 Kg/m2; Treatment 3: -0.5% HbA1c, BMI -1 
Kg/m2 and 2 non-severe hypoglycemia (NSHE) avoided; Control: no effect. 
Lifetime analyses were conducted using NHANES to populate the patient 
characteristics in the modeling. Disutilities of -0.0052 and -0.0038 were applied to 
each NSHE and 1 unit increase in BMI respectively. Discounting was applied at 
3% and US 2010 costs were used. RESULTS: Compared to Control (no effect), 
Treatments 1, 2 and 3 were associated with discounted gains in lifetime quality 
adjusted life expectancy (QALE) of 0.059, 0.119 and 0.241 respectively (0.091, 0.185 
and 0.354 undiscounted). Each unit decrease in NSHE and BMI were associated 
with similar gains in QALE associated with a 0.5% HbA1c reduction. 
CONCLUSIONS: Within models of T2DM, the health utility gains associated with 
weight reduction and avoidance of NSHE are applied to all patients in a 
treatment arm; this is in contrast to changes in HbA1c that only impacts the 
probability of a future event (cardiovascular and/or micro-vascular). 
Consequently, therapies associated with the avoidance of weight gain and 
hypoglycaemia will likely exhibit favourable cost-effectiveness profiles 
compared to improvements in glycaemic control only.  
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OBJECTIVES: Accurate estimation of baseline cardiovascular (CV) risk and 
relative risk reduction (RRR) is crucial to ensure that economic evaluations of 
new health technologies for the treatment of type 2 diabetes (T2DM) are robust. 
Many economic models (such as the CORE Diabetes Model) use risk equations 
(RE) derived from UKPDS and concerns persist regarding their validity; 
particularly as new equations are published. The objective of this study was to 
compare the consistency of predicted CV risk using RE derived from various 
T2DM populations. METHODS: All CV equations identified from a recent 
systematic review, derived from populations with T2DM, were coded and 
validated. Equations from Australia (Fremantle), New Zealand (DCS), Sweden 
(Cederholm), China (Yang), Scotland (DARTS), USA (ARIC) and UK (UKPDS) were 
included. Predicted 5-year CV risk was obtained using baseline cohort 
characteristics taken from ACCORD. Relative risk reductions (RRR) were obtained 
by applying a 10% relative reduction in HbA1c, total cholesterol and SBP both 
individually and in combination. RESULTS: Mean 5-year predicted risk of CVD 
was 11.0% (SE 1.9%); minimum of 3.4% (ARIC) and maximum 20.7% (DARTS). A 
10% reduction in HbA1c, TC and SBP resulted in a mean RRR of 6.4%(SE 0.7%), 
6.8% (SE 1.5%)and 9.8% (SE 2.3%) respectively. The DCS equation (New Zealand) 
predicted the lowest RRR for HbA1c, TC and SBP reduction (4.3%, 1.0% and 3.5% 
respectively). The highest RRR for HbA1c change was Cederholm (8.3%) and the 
DARTS equation for TC and SBP, 10.3% and 18.9%, respectively. CONCLUSIONS: 
The difference in absolute risk across these equations does not appear 
dependent on geographical location or study recruitment period. Generally, the 
UKPDS equations produced consistent absolute CV risk and RRR estimates close 
to the group averages; this is of reassurance given their widespread use. Health 
care policy decisions that rely on CV risk estimation should perform sensitivity 
analysis across multiple equations where practicable.  
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OBJECTIVES: There is a substantial body of epidemiological evidence relating 
body-mass index (BMI) to increased risk of mortality in subjects with type-2 
diabetes mellitus (T2DM). Cardiovascular (CV) and mortality risk equations 
typically incorporate the effects of elevated BMI via the inter-relationship 
between modifiable CV risk factors (cholesterol and systolic blood pressure) and 
BMI; this approach may underestimate true mortality risk. Therefore, the 
objective of this study was to assess by how much existing risk equations 
underestimate the risk of mortality as a function of increasing levels of BMI. 
METHODS: We projected life expectancy (LE) using the IMS CORE Diabetes Model 
(CDM), a validated and widely used simulation model designed to predict the 
health care costs and benefits associated with diabetes. Projected LE was 
obtained using patient level data (PLD) for subjects with T2DM from NHANES. CV 
and mortality risk was assessed using UKPDS risk equations and additional BMI 
cause specific mortality included via results from published prospective analyses 
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of 900,000 adults. Multiple linear regression analysis of simulation output 
relating LE to levels of BMI was conducted using R. RESULTS: Results were 
obtained for 1855 subjects with mean age 63.6 years, 53% male; 16% current 
smokers; duration of diabetes 9.5 years; HbA1c 7.4%; SBP 135mmHg; total 
cholesterol 195mg/dl and BMI 30.6kg/m2. Using UKPDS mortality risk the 
predicted mean discounted LE was 11.8 years with each unit increase in BMI 
associated with a 0.06 years less life expectancy. Using BMI cause specific 
mortality decreased mean discounted LE to 10.85 years; with each unit increase 
in BMI linearly associated with a 0.2 years reduction in LE. CONCLUSIONS: 
Failure to adequately incorporate the deleterious effect of increasing levels of 
BMI on risk of mortality may substantially distort the health economic 
assessment of type-2 diabetes specific therapies; particularly those associated 
with the avoidance of weight gain or weight loss.  
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OBJECTIVES: To review and systematically synthesize the cost-effectiveness of 
diabetes interventions. METHODS: We conducted a systematic review of cost-
utility analyses (CUAs) related to diabetes published between 1994 and 2012, 
using the Tufts Medical Center Cost-Effectiveness Analysis Registry 
(www.cearegistry.org). We described the study characteristics, such as country, 
type of interventions, perspective, funder, and whether the intervention was 
recommended by the American Diabetes Association (ADA) guidelines. We also 
examined the distribution of the incremental cost-effectiveness ratios (ICERs) 
and used logistic regression to identify factors independently associated with 
favorable ratios (defined as less than the median of all diabetes-related ICERs). 
RESULTS: We identified 167 CUAs from over 20 countries, pertaining to 
interventions for Type 1, Type 2, gestational diabetes mellitus, and diabetes 
complications and comorbidities. Studies conducted in the US and UK accounted 
for 40% and 18% of all CUAs, respectively. Fifty-four percent of diabetes CUAs 
examined pharmaceuticals; 70% focused on tertiary prevention. Most (88%) used 
a health care payer perspective and more than half (52%) were industry-
sponsored. Of 425 published cost-utility ratios, 80% examined an ADA-
recommended intervention (e.g. annual retinopathy screening) relative to a 
comparator. Approximately 71% of interventions examined in diabetes CUAs 
were either cost-saving or below $50,000 per QALY, regardless of whether the 
service was recommended by the ADA. Logistic regression analysis showed that 
CUAs conducted from the US perspective were more likely to report favorable 
ratios than non-US CUAs (OR=2.45; 95% CI=1.12, 5.38). Ratios for diagnostic or 
screening tests were more favorable than other intervention types (OR=3.75; 95% 
CI=1.03, 13.66). CONCLUSIONS: Most interventions examined in diabetes CUAs 
were recommended by the ADA and demonstrated good value for money. 
Further studies are needed to explore the utilization of interventions with 
favorable ratios using the real world data.  
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HYPOGLYCAEMIC EPISODES (NSHE) IN PATIENTS TREATED WITH 
SULFONYLUREA OR DPP4 DUAL COMBINATION ORAL THERAPY  
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OBJECTIVES: Hypoglycemia is a major consideration in the management of 
blood glucose in people with type 2 diabetes. NSHE occur more frequently than 
severe episodes and account for the majority of hypoglycemic burden. Recent 
data has quantified the per-event costs of NSHE in terms of productivity loss and 
out-of-pocket expenses. The aim of this study was to model the cost 
implications for NSHE in relation to sulfonylurea or DPP-4 based dual 
combination blood glucose lowering regimens METHODS: Published patient 
source data was used to obtain workplace productivity costs, out-of-pocket (OOP) 
expenses and estimates of the frequency of NSHE. The IMS CORE Diabetes Model 
(CDM) a validated and widely used simulation model was initiated with dual 
therapy patient profiles derived from NHANES and efficacy profiles for 
metformin + sulfonylurea (M+S) versus metformin + DPP-4 (M+D) obtained via a 
mixed treatment comparison. Costs (2010) and benefits are in USD and 
discounted at 3%. RESULTS: In the published patient source data mean weighted 
productivity cost of each NSHE was $34.87 with monthly OOP of $35.56 with 
24.9% of T2DM patients reported NSHE frequency of ‘daily’ to “about 1/week”. 
Assuming a frequency of 1 NSHE per week M+D is associated with an 
incremental annual cost of $212 compared to M+S when including productivity 
and OOP expenses over a 1-year period . Over a lifetime, discounted cost per 
quality adjusted life year gained was $2,419. CONCLUSIONS: Sulfonylurea based 
dual combination therapy is potentially associated with substantially greater 
economic consequences for employers and patients compared with DPP4 based 
dual therapy regimens. Therefore greater consideration should be given to the 
productivity related consequences of hypoglycaemia with respect to dual 
therapy escalation, particularly in people with type 2 diabetes of a working age.  
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OBJECTIVES: Limited data exist on the use of health care resources due to 
hypoglycaemia induced by insulin therapy in diabetes patients. This study 
investigated the frequency of patient-reported non-severe hypoglycaemic events 
(NSHE) in type 1 (T1) and insulin-treated type 2 (T2) diabetes patients and their 
impact on health care resource use in Belgium. METHODS: T1 and T2 diabetes 
patients aged > 15 years were recruited via existing panels to complete four 
questionnaires collecting data at weekly intervals. In addition to demographics, 
data were collected on frequency of NSHE with a 7-day recall period, as well as 
data including impact on patient well-being, work productivity and health care 
resource use. NSHE was defined as an event with symptoms of hypoglycaemia, 
with or without blood glucose measurement (BGM), or low BGM without 
symptoms, which the patient could manage without assistance. Severe 
hypoglycaemic events (SHE), an event needing help from a third party to 
manage, were also reported. RESULTS: Overall, 412 patients (44% T1, 56% T2) 
completed 1148 patient-weeks. Mean NSHE per patient-week were 2.3 in T1 
patients and 0.7 in T2 patients. Following their last NSHE, 64% patients reported 
feeling tired/fatigued, 59% feeling less alert and 37% feeling ill/uncomfortable. 
Over the 7 days following a NSHE, BGM test-strip use increased by 3.4 (mean).  In 
employed patients (38%), 13% of  NHSE were associated with lost work time.  
Following daytime NSHE, 6% of T1 patients and 17% of T2 patients contacted a 
health care professional, plus 8% of T1 and 6% of T2 following a nocturnal NSHE. 
Mean annual frequency of SHE was 0.6. Of the 124 patients reporting a SHE, 17% 
required emergency visits. CONCLUSIONS: NSHE have an economic burden with 
a negative impact on patient well-being. However, the real burden of 
hypoglycaemia may be underestimated since few patients report events to a 
health care professional.  
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OBJECTIVES: Hypoglycaemia is a frequent side effect of insulin treatment for 
patients with diabetes and can impact on quality of life, well-being, work 
productivity and health care resources. This study explored patient-reported 
frequency of non-severe hypoglycaemic events (NSHE) and the impacts of these 
events on patients’ lives and health care resource use in Germany. METHODS: 
Patients over 15 years of age with Type 1 (T1) or insulin-treated Type 2 (T2) (basal 
only T2BOT; basal-bolus T2BB and other regimen T2O) diabetes were recruited in 
Germany via online panels to complete four questionnaires at weekly intervals. 
Data were collected on hypoglycaemia-related resource use and the impact of 
the last hypoglycaemic event on patient well-being and work productivity. NSHE 
was an event with symptoms of hypoglycaemia, with or without blood glucose 
measurement (BGM), or low BGM (≤ 3.1 mmol/l) without symptoms, which the 
patient could manage without assistance. RESULTS: In total, 614 patients (34% 
T1 and 66% T2) participated in the study. Overall self-reported mean NSHE were 
1.0 per patient week (1.6 for T1, 0.6 in T2BOT, 0.6 in T2BB and 0.8 in T2O). 
Following the last NSHE, 64% of patients reported feeling tired/fatigued with 51% 
and 39% feeling less alert and nervous/anxious, respectively. Overall 
employment rate was 53%. A total of 14% of patients reported loss of work time 
due to the last NSHE. Mean increase in BG test-strips use was 3.86 over the 7 
days following each NSHE equating to an estimated additional resource use of 
€2/patient/event (cost/strip €0.5). Following a daytime NSHE 14% of T1 and 23% 
of T2 patients contacted a health care professional (nurse/physician), plus 16% of 
T1 and 13% of T2 patients following night-time events. CONCLUSIONS: NSHE 
have a negative impact on patient well-being and are associated with work time 
loss and increased use of health care resources in Germany.  
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OBJECTIVES: Hypoglycaemia has negative implications for healthcare resources 
and diabetes patients’ quality of life. However, there are limited data available 
on hypoglycaemia in a real-world setting. This study investigated the economic 
and health-related impact of self-reported non-severe hypoglycaemic events 
(NSHE) and severe hypoglycaemic events (SHE) in Spain. METHODS: Patients 
over the age of 15 with type-1 (T1) or insulin-treated type-2 (T2) diabetes were 
recruited via existing panels to complete four questionnaires at weekly intervals. 
Data were collected on frequency of NSHE and SHE, and their impact on patient 
well-being, work productivity and health care resource use. NSHE was defined as 
an event which the patient could manage without assistance and SHE as an 
event needing help from a third party to manage. RESULTS: In total, 630 patients 
completed 2238 patient-weeks. Mean self-reported NSHEs per patient week were 
1.7 in T1 patients and 0.5 in T2 patients. After their last NSHE, 67% of patients 
reported feeling tired/fatigued with 45% feeling less alert and 42% feeling 
ill/uncomfortable. Over the seven days following a NSHE, blood glucose 
measurement test-strip use increased by a mean of 5.3. In employed patients 
(43%), 18% of NSHE were reported to lead to lost work time. A total of 8% of T1 
and 20% of T2 patients contacted a health care professional following a daytime 
NSHE, and 12% (T1) and 20% (T2) following a night-time NSHE. After a SHE, 30% 
of patients required emergency visits. CONCLUSIONS: Hypoglycaemic events are 
a common occurrence in T1 and insulin-treated T2 patients in Spain and present 
an economic burden through increase in health care-resource use and work time 
loss. They also have a negative impact on patient well-being. However, the real 
burden of hypoglycaemia may be underestimated as events are often not 
reported to a health care professional. 
